Nasdaq Markets

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

(RTTNews) - Below are the earnings highlights for Las Vegas Sands Corp. (LVS):

(RTTNews) - CSX Corp (CSX) revealed a profit for first quarter that dropped from last year.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

What happened Shares of Transocean (NYSE: RIG) sank 12.7% by 3 p.m. EDT on Wednesday. Weighing on the offshore drilling company was an analyst downgrade. 

What happened Shares of brick-and-mortar retail companies were moving lower on Wednesday, after a leading provider of store-credit cards said that charges fell sharply after mid-March, when stores closed in response to the outbreak of the COVID-19 virus.

Toyota Motor (NYSE: TM) will cut its auto production in Japan by about half from its most recent plan next month, a move that will affect 18 of the company's factories and dozens of suppliers, according to a Nikkei report on Wednesday.

What happened Airline shares were under pressure Wednesday after Delta Air Lines (NYSE: DAL) became the first in the sector to post first-quarter results. Delta actually lost less money in the quarter than analysts had anticipated, but the airline was clear that things have only

What happened  Shares of Expedia Group (NASDAQ: EXPE) jumped as much as 12% on Wednesday after rumors spread that the online travel specialist could receive a $1 billion investment. As of 2:40 p.m. EDT, the stock was up 7.6%. 

While Wall Street analysts were lowering their estimates on Facebook FB because of an uncertain outlook for advertising in the foreseeable future, the company was finalizing a deal for a 10% stake in India’s Reliance Jio.

The U.S. Energy Information Administration (EIA) released its weekly petroleum status report on April 22, and the numbers show that consumption of refined products has collapsed and oil producers have been slow to respond with corresponding production cuts, causing oil prices to

Unlike other smaller healthcare companies, powerhouse Abbott Laboratories (ABT) hardly needed a global pandemic to raise awareness. The healthcare giant was performing well before the viral outbreak, but a slew of good news has just pushed its share price up to a new all-time high of $100.

The company released its quarterly results last Thursday, delivering solid beats across the board. Specifically, revenue came in at $7.7 billion, indicating organic growth of 4.3%, while EPS hit $0.65, 4 cents above the estimates and exhibiting growth of 3.2%. On account of the economic uncertainties due to COVID-19, the company suspended guidance for 2020.

The positive print isn’t much of a surprise. Over the last five years, Abbot has beaten top and bottom-line expectations in most quarters.

But according to Credit Suisse’s Matt Miksic, the real good news was in the details.

“Perhaps the most significant takeaways from Q1 results and management commentary related to the substantial increase in volumes and growth in new COVID-19 tests,” the 5-star analyst said, adding, “We view this wave of new tests as a significant new growth driver for ABT over the next 2-3 years, and expect consensus estimates and growth expectations to rise accordingly in the coming months.”

Over the past several weeks, Abbot has launched three approved COVID-19 tests; two molecular tests on the company’s ID NOW point-of-care platform and m2000 lab-based platform and a lab-based serology blood test. The company expects to add two more in the coming weeks; a lateral flow serological test and an additional lab-based serology test.

“We estimate this wave of COVID-19 tests could reach annual volumes in 2021 of ~50 mil for molecular and ~550 mil serological, driving significant incremental Diagnostics sales of $2.7 bil and 85c to sales and EPS for 2021, respectively, and continued growth in 2022,” Miksic noted.

Accordingly, the top analyst reiterated an Outperform on Abbot along with raising the price target – bumped up from $95 to $106. Upside from current levels is 10%. (To watch Miksic’s track record, click here)

All in all, the rest of the analyst community backs up Miksic’s call. A strong Buy consensus rating is based on 9 Buys and 3 Holds. At $103.85, the average price target implies upside of 9% in the year ahead. (See Abbott stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Imbruvica, a blockbuster cancer drug marketed by Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), recently secured its 11th approval. On Tuesday, the Food and Drug Administration approved the combination of Imbruvica and Rituximab as a treatment for patients with previ

What happened Shares of Chipotle Mexican Grill (NYSE: CMG) were soaring today after the company delivered a first-quarter earnings report that calmed investors and convinced them that the burrito chain would not only survive the pandemic, but come out even stronger on the othe

Image source: The Motley Fool.

Image source: The Motley Fool.

Image source: The Motley Fool.

Image source: The Motley Fool.

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Cantel Medical Corp (Symbol: CMD) is one of the most shorted stocks of the Russell 3000, based on 6.04 "days to cover" versus the median component at 5.30. There are a number of

With a number of countries under lockdowns to contain the spread of the coronavirus, the trend of working from home (WFH) has picked up. The successful execution of the WFH policy suggests that the trend is going to be a new normal over a long haul.